Tag: Ferring

 

Ferring Pharmaceuticals to Share New Reproductive Medicine Data at ASRM 2020 Scientific Congress & Expo

Ferring Pharmaceuticals (US) today announced that it will present eleven company-sponsored abstracts, including six oral presentations, at the American Society for Reproductive Medicine (ASRM) 2020 Virtual Scientific Congress & Expo taking place October 17-20, 2020.

“We look forward to presenting data at this year’s ASRM congress, where leaders will gather virtually to share meaningful research that advances scientific knowledge in the field of reproductive medicine,” said Gaurang Daftary, M.D., M.B.A, Vice President, Reproductive Medicine and Maternal Health at Ferring Pharmaceuticals. “At Ferring, we are committed to addressing the medical needs of patients through the advancement of science. Our presence at ASRM this year underscores that commitment.”

Ferring’s first oral presentation highlights data from a clinical trial involving infertile women with primary hypothalamic amenorrhea, a rare patient population that is unable to ovulate and achieve pregnancy due to deficiencies in their brain’s production or secretion of a key peptide called Gonadotropin Releasing Hormone (GnRH).

Additionally, the company will present three new sub analyses of data from the recently published MEGASET-HR trial. The first abstract characterizes differences in ovarian response dependent upon the type of gonadotropin used and baseline levels of anti-Müllerian Hormone (AMH), a marker of ovarian reserve. The second presents a possible relationship between serum levels of human chorionic gonadotropin (hCG) at the end of stimulation and live birth. The third abstract from the MEGASET-HR trial describes outcomes from the transfer of fresh or frozen embryos designated as normal based on assessment of the number of chromosomes.

The details of all Ferring abstracts presented at the meeting are as follows:

Oral (O-33):
Title: Pulsatile Gonadotropin Releasing Hormone (GnRH) via Subcutaneous Pump for the Treatment of Primary Amenorrhea Associated with Hypogonadotropic Hypogonadism
Date and Time: Saturday, October 17, 2020; 2:30 PM-2:45 PM

Oral (O-169):
Title: Safety evaluation of a novel progesterone vaginal ring (PVR) in luteal phase support: SARA trial results
Date and Time: Monday, October 19, 2020; 1:50 PM-2:05 PM

Oral (O-223):
Title: Differential Ovarian Response to Gonadotropin Preparations Despite Similar Ovarian Reserve: MENOPUR in GnRH (Gonadotropin Releasing Hormone) Antagonist Single Embryo Transfer – High Responder (MEGASET-HR) Trial Analysis
Date and Time: Tuesday, October 20, 2020; 1:50 PM-2:05 PM

Oral (O-224):
Title: Serum gonadotropin association with live birth in high-responders undergoing ovarian stimulation: MENOPUR in Gonadotropin Releasing Hormone (GNRH) Antagonist Single Embryo Transfer – High Responder (MEGASET-HR) trial analysis
Date and Time: Tuesday, October 20, 2020; 2:05 PM-2:20 PM

Oral (O-225):
Title: Fresh versus frozen euploid blastocyst transfer outcomes in predicted high-responders: MENOPUR in GNRH (Gonadotropin Releasing Hormone) Antagonist Single Embryo Transfer – High Responder (MEGASET-HR) trial analysis
Date and Time: Tuesday, October 20, 2020; 2:20 PM-2:35 PM

Poster (P-443):
Title: Similar ovarian response with individualized follitropin delta dosing regimen in Japanese and non-Japanese IVF/ICSI patients
Date and Time: Monday, October 19, 2020; 4:30 PM-6:00 PM

Poster (P-591):
Title: Atosiban and Barusiban improved impaired endometrial blood flow in pregnant rabbits
Date and Time: Monday, October 19, 2020; 4:30 PM-6:00 PM

Poster (P-458):
Title: Similar dose-response profiles for